Authored by Les-leigh A
Let’s be honest – nobody saw quite how fast this would move.
In just a few months, Microsoft, Amazon and OpenAI have all planted flags in consumer health AI. Microsoft’s Copilot Health went live this month, built as a secure, standalone space inside Copilot where your wearables, lab results and medical records actually start talking to each other. Amazon wasn’t far behind, launching its Health AI assistant with a focus on the practical stuff: booking appointments, making sense of prescriptions, explaining what your records actually mean. Furthermore, OpenAI’s ChatGPT Health and Anthropic’s Claude for Healthcare made their debut in January.
Four of the biggest names in tech. One sector. A matter of months. For the HealthTech startups who’ve been quietly building in this space for years, it’s a lot to absorb.
Why Big Tech Wants Your Health Data
Here’s the thing about health data: there’s an enormous amount of it, and almost none of it is being used well. Your GP has one set of records. Your hospital has another. Your Garmin or Apple Watch is collecting data that never makes it anywhere meaningful. It’s fragmented, siloed and mostly useless in its current state.
That’s the gap these platforms are going after. The pitch isn’t complicated: let us bring it all together and we’ll show you something useful. Microsoft is emphasising the trust angle with Copilot Health, which makes sense given how sensitive this data is. Amazon is going more practical – less “insight”, more “here’s what your prescription actually means and here’s where to get it filled.” OpenAI is targeting medical record integration.
Different entry points, same destination.
Whoever gains the trust of consumers and healthcare providers in this space will possess one of the most valuable data assets imaginable. That’s why the debate around data ownership and AI is only getting louder. And the health sector just turned the volume up significantly.
More from Artificial Intelligence
What Happens To The Startups Already In This Space?
This is the question worth contemplating. The arrival of Big Tech in a market does two things simultaneously: it validates everything the early builders were doing, while also making their lives considerably harder.
The data problem is the most critical part of this. Microsoft and Amazon enter the space with existing relationships across hospitals, insurers and enterprise health systems. They don’t need to build trust from scratch in the way a Series A startup has to. They already have distribution and data – these are the chief advantages.
But healthcare isn’t like other markets. Clinical accuracy matters in a way it simply doesn’t in, say, productivity software – getting it wrong has real consequences. And that means regulatory compliance, rigorous testing and genuine clinical credibility aren’t optional extras – they’re everything. UK and European startups, working within GDPR and the EU AI Act, are actually positioned well here. The constraints that feel like friction are also what builds credibility. Startups like Matresa, tackling maternal health in the UK with a clinically grounded approach, are a good example of what that looks like in practice.
It’s worth noting that we’ve seen these dynamics before, just in a different corner of tech. The fitness and wearables data space has spent years working through exactly these questions about who owns user data, who controls it and what happens when big platforms decide they want a piece of it. Health AI is heading down the same road, just with higher stakes.
The Opportunity Hidden In The Noise
So is this purely bad news for HealthTech startups? Not really, no.
When a market gets this kind of attention from players with Microsoft and Amazon’s marketing budgets, the entire category inevitably grows. Consumer awareness of health AI is about to jump in a way that no startup could have driven on its own. More people engaging with digital health tools means a bigger overall market, and that includes the more specialised players building for specific conditions, communities or care pathways.
The startups with the strongest position going forward are the ones doing things the general-purpose platforms genuinely can’t. Women’s health. Rare diseases. Mental health. Post-operative care. Chronic condition management. These aren’t areas where scale alone wins. They’re areas where clinical depth, community trust and real specialist knowledge are the differentiators. These things don’t come from a platform launch, however well-funded.
Big Tech is coming for health data. That much is clear. But the companies building something specific, human and genuinely trusted? There’s still a lot of room for them.
